SUMMARY To evaluate the response during insulin-induced hypoglycemia, diabetics treated with relatively selective or nonselective jQ-adrenergic blocking agents were studied. Placebo, atenolol (100 mg/day), and propranolol (80 mg b.i.d.) were administered to 12 insulin-treated diabetics for 1 week in a double-blind, randomized, crossover fashion with a 2-week washout between treatments. Sufficient intravenous insulin (0.2-0.6 units/kg) was administered to decrease plasma glucose 68% from the basal level or to less than 60 mg/dl within 90 minutes. Blood pressure changes at the nadir of plasma glucose were +15.2/ -9.9 mm Hg for placebo, +27.9/0 mm Hg for atenolol, and + 38.8/+ 14.3 mm Hg for propranolol. Diastolic blood pressure changes induced by propranolol were significantly different from those induced by atenolol (p < 0.01) and placebo (p < 0.01), and systolic pressure changes were significantly different (p < 0.02) between propranolol and atenolol. Mild seizures developed in two patients treated with propranolol. Their blood pressure changes at the plasma glucose nadir were +56/+ 22 and +86/+ 31 mm Hg. Other symptoms of hypoglycemia were more frequent during /3-blocker than during placebo treatment. Differences in response may be related to the relatively selective adrenergic blocking effect of these drugs. (Hypertension 7: 443-446, 1985) KEY WORDS • hypoglycemia • glucose • insulin • atenolol • propranolol • placebo T HE use of /3-adrenergic blocking agents in insulin-treated diabetic patients has caused considerable concern. This concern stems from the fears that hypoglycemia may occur more frequently and with greater severity, that the premonitory symptoms will be unrecognized, that the glycemic recovery will be impaired, or that the associated hypertensive response will be dangerous.
T HE use of /3-adrenergic blocking agents in insulin-treated diabetic patients has caused considerable concern. This concern stems from the fears that hypoglycemia may occur more frequently and with greater severity, that the premonitory symptoms will be unrecognized, that the glycemic recovery will be impaired, or that the associated hypertensive response will be dangerous. 1 " 4 Furthermore, the role of relatively selective /3,-adrenergic antagonists in this process has been questioned. 5 -6 This study was designed to address these issues in a group of insulin-treated diabetic patients.
Methods
Twelve insulin-treated diabetic patients were selected for this study after having signed informed consent (11 women, 1 man; mean age, 52.2 ±6.78 years). All concomitant drug therapy, with the exception of insulin, was discontinued 1 week before the start of this study. Insulin was taken until the day before the study. The patients received in a randomized, double-blind, crossover fashion either placebo, atenolol, 100 mg/day, or propranolol, 80 mg twice daily, for 1 week. There was a 2-week washout between each of these treatment periods. At the end of each week of treatment, a sufficient amount (0.2-0.6 units/kg of body weight) of intravenous insulin was administered to induce a 68% decrease in plasma glucose from the basal concentration or a reduction to 60 mg/dl or less within 90 minutes. The patients were given nothing by mouth after 2200 hours on the evening before the insulin infusion test. At 0800 on the morning of the insulin infusion test, the double-blind medication was administered. At 1100 hours regular insulin was administered by intravenous bolus. At 1130, if the capillary blood glucose levels had not decreased as defined, additional intravenous insulin was administered. At 0, 30, 60, 120, and 150 minutes after the initial intravenous insulin and at least 120 minutes after hypoglycemia, capillary blood glucose and venous plasma glucose levels, blood pressure, and pulse, were measured and symptoms were evaluated. The studies were performed in a clinical research unit under the careful supervision of a medical and nursing staff.
Results
All of the patients participating in this study were over the age of 40, predominantly black, and all except one were women (Table 1) . They had been diabetic for an average of 9.5 years. All were insulin-treated, but C-peptide responsiveness was not evaluated to determine if they were truly insulin dependent. Most were obese, and there was probably some degree of insulin resistance, particularly in view of the insulin doses required to induce hypoglycemia (0.2-0.6 units/kg), which suggests that at least some of the patients had non-insulin-dependent diabetes mellitus.
There was no statistically significant difference in the baseline mean plasma glucose concentrations (198.8 ± 49, 173.6 ± 36, 187.4 ± 61 mg/dl for placebo, atenolol, and propranolol respectively) before each insulin infusion test, nor in the insulin doses administered (33 ± 15.3,31.3 ± 11.7,29.2 ± 1 1 . 8 units; Table 2 ). The decrement in plasma glucose levels after insulin administration correlated with the baseline values, being greatest for placebo and least for atenolol ( Figure 1 ). Somewhat surprisingly, the symptoms of hypoglycemia were not significantly different (although slightly more frequent after propranolol and atenolol than after placebo treatment; Table 3 ). After propranolol treatment, however, two patients experienced mental confusion and had some twitching motions that probably represented mild seizures. Neither patient had tonic or clonic movements or lost consciousness, and both responded promptly to intravenous glucose. At nadir their plasma glucose concentrations were similar to those following atenolol and placebo: 48 versus 39 versus 32 mg/dl and 22 versus 21 versus 20 mg/dl for placebo, atenolol, and propranolol respectively.
TABLE 2 (continued).
There were some differences in blood pressure and pulse changes. Baseline systolic and diastolic blood pressures were lower for propranolol than for placebo (p > 0.05). As would be expected, systolic blood pressure increased at the plasma glucose nadir after all three treatments. The increase was greater following propranolol and atenolol treatment than after placebo. The increase following atenolol treatment was less than that following propranolol. Diastolic blood pressure decreased following placebo, did not change with atenolol, and increased by an average of 14.3 mm Hg with propranolol treatment. The changes were statistically significant between propranolol and placebo (p < 0.01) and propranolol and atenolol (p < 0.01). Maximal blood pressure changes did not always occur at the time of plasma glucose nadir. These maximal changes were 8/-15.9, 33.7/ -5 . 7 , and 49.2/19.6 mm Hg for placebo, atenolol, and propranolol respectively. Interestingly, the two patients who suffered mild seizures while receiving propranolol had maximal The pulse increased with placebo treatment but decreased significantly after atenolol (p < 0.01) at the plasma glucose nadir. This reduction in pulse was more pronounced with propranolol than with atenolol treatment.
Discussion Insulin-induced hypoglycemia in this group of diabetic patients previously treated with insulin produced differences in blood pressure response between a relatively selective and a nonselective /3-blocker. The diastolic and systolic blood pressure responses were greater after propranolol than following atenolol or placebo treatment. The patients who had mild seizures were receiving propranolol and had maximal blood pressure responses of + 56/ + 22 and + 86/ + 31 mm Hg respectively. 1 It seems possible that the combination of hypoglycemia and the associated hypertensive response may have had additive or synergistic effects in surpassing the seizure threshold. A number of studies have shown hypertensive responses during hypoglycemia with propranolol treatment.
3 -7 -8 These responses generally have been greater than those observed with relatively selective /3-blockers. 3 8 It is of interest that six of the seven patients with the greatest hypertensive response to hypoglycemia previously had been receiving antihypertensive therapy. A carryover effect from the antihypertensive therapy or its withdrawal is doubtful because there was a 1-week washout before screening, usually an additional week following screening before a patient was randomized to a particular treatment, and a 2-week washout period between each 1-week treatment period.
Whether hypertension per se results in a more labile blood pressure response during hypoglycemia is not known, but remains a possibility. It is also possible that the neuropathic effects of diabetes may sensitize the patient to the effects of catecholamines, so that there could be a greater response to norepinephrine. Nies and Shand 9 have suggested that propranolol can potentiate the pressor activity of catecholamine metabolites.
In choosing therapy for an insulin-treated diabetic patient, some consideration must be given as to whether to use any /3-blocker. The results of this study suggest that use of a relatively selective /3-blocker would be advantageous; atenolol seemed to have a vascular sparing effect in this setting and did not result in such dramatic elevations of blood pressure associated with hypoglycemia. The effect of atenolol on blood pressure and pulse was comparatively less severe than that of propranolol. The symptoms of hypoglycemia were •not suppressed by either /3-blocker as compared with placebo. This early fear has not been supported by data from this or other recent studies. As the hypoglycemia seemed to be better tolerated during atenolol treatment, the choice of a cardioselective agent would seem to be preferable if an insulin-treated diabetic patient needs treatment with a /3-blocking agent.
